(PGRX) Drilling Update: In-fill Drilling Program Meeting Targets

Prospect Global Resources, which controls a superb 90k acre site (state and private leases) in eastern Arizona’s Holbrook Basin that hosts a nice, relatively shallow potash deposit (around which the company intends to construct a state-of-the-art production facility), reported good news today out of an update to markets on their previously announced in-fill drilling program at the site.

President and CEO of PGRX, Damon Barber, commented on the successful completion of seven drill holes in the program, three of which were done as step-outs to expand the resource base, saying that the company is well on track for converting a significant volume of inferred category resources to measured and indicated. KR-2 seam potash (primary target) was intercepted in all four in-fill holes, as well as two of the step-out holes, something which should beef up the coming Definitive Feasibility Study figures nicely and Barber was especially pleased at the step-out work success, as it roundly extends overall mine life.

The fundamental development model for the site is largely reinforced by this latest drilling and is enhanced by the step-out data as well, as the company readies their initial sample batch for assay by SRC. The Holbrook Salt Basin itself sits in the Permian Supai Salt Formation’s upper layer, which is rich in potash and economically mineable at depths closer to Intrepid’s Carlsbad Mine in New Mexico, much shallower than other potash deposits currently on the global stage. The idea of churning this stuff out in eastern AZ via a state-of-the art facility is sound and the existing logistics, as well as direct access to primary regional ports and thus end markets, makes the deposit metrics all the sweeter.

The company will be chasing two distinct seams of potash in the Supai Formation, but the KR-1 is more erratic and thus the KR-2 will be the main focus. The NI 43-101report from 2012 on the Holbrook Project Resource used a 40%-foot cutoff and produced some handsome estimates, with 102.7M tons (5.7M measured, 44.2M indicated and 52.8M inferred) of Potassium Chloride (KCI) total and Sylvinite (halite, or sodium chloride and KCI mixture) totals across all categories as high as 634.1M tons (36.8M measured, 286.0M indicated and 311.3M inferred), so this latest drilling data has people at PGRX really buzzing with excitement. Average KCI grade in the measured category was 15.48% with very low carnallite and lower insoluble content than currently seen over at Intrepid’s Carlsbad Mine.

Additional drill work at the Holbrook Project includes another six holes, five of which are down past 1k feet or more and a sixth of which was down to around 520 feet as of this morning (Sep 4). This puts PGRX easily in striking distance of the eight hole development milestone target for Nov 1 as per their current debt agreement and investors will be really eager to get a look at the upcoming Definitive Feasibility Study. Smart moves by PGRX with potash currently stabilized at just under $400/ton amid growing demand from the global agribusiness sector despite last month’s shakeup with Russian giant Uralkali dropping out of the Belarusian Potash cartel. The potash space has become more competitive now and PGRX is really on the ball when it comes to creating a model that can succeed and thrive.

Regarding Forward-Looking Statements

With the exception of historical matters, the matters discussed in this press release include forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from projections or estimates contained herein. Such forward-looking statements include statements regarding current and future classification of Prospect Global’s potash resources, development of its potash resources and potash mining facility and the Pre-Feasibility Study. Factors that could cause actual results to differ materially from projections or estimates include, among others, potash prices, economic and market conditions, and the additional risks described in Prospect Global’s filings with the SEC, including Prospect Global’s Annual Report on Form 10-K/A for the year ended March 31, 2013. Most of these factors are beyond Prospect Global’s ability to predict or control. The forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, Prospect Global does not assume any obligation to update any forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements.

About Prospect Global Resources Inc.

Prospect Global Resources Inc. is a Denver-based company engaged in the exploration and development of a potash mine located in the Holbrook Basin of eastern Arizona. Prospect Global’s stock is traded on the NASDAQ Capital Market under the ticker symbol PGRX.

Additional details about Prospect Global Resources Inc. can be viewed at the Company’s website, www.prospectgri.com.

(HOTR) / Hooters, International Franchise Operator Update

(GALE) to Present at the Rodman & Renshaw Annual Global Investment Conference

PORTLAND, Ore., Sept. 4, 2013 — Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company commercializing and developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President & Chief Executive Officer, will present a corporate update at the Rodman & Renshaw Annual Global Investment Conference. The presentation will take place on Monday, September 9, 2013 at 10:25 a.m. ET at the Millennium Broadway Hotel in New York, NY.

The presentation will be webcast and available on the Investors section of the Company’s website at www.galenabiopharma.com.

About Galena Biopharma

Galena Biopharma, Inc. (Nasdaq:GALE) is a Portland, Oregon-based biopharmaceutical company commercializing and developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. For more information please visit us at www.galenabiopharma.com.

CONTACT: Remy Bernarda
         Senior Director, Communications
         (503) 405-8258
         rbernarda@galenabiopharma.com

(INO) Pharmaceuticals to Present at Upcoming Investor Conferences

BLUE BELL, Pa., Sept. 3, 2013 — Inovio Pharmaceuticals, Inc. (NYSE MKT: INO), announced today that Dr. J. Joseph Kim, President and CEO, will be presenting a corporate overview of the company at the Rodman & Renshaw Global Investment Conference and the Stifel Nicolaus Weisel Healthcare Conference.

Rodman & Renshaw Annual Global Investment Conference

September 8-10, 2013
Millennium Broadway Hotel
New York, NY

Inovio Presentation
Tuesday, September 10, 2013
11:15 AM ET

Stifel Nicolaus Weisel Healthcare Conference

September 11-12, 2013
Four Seasons Hotel
Boston, MA

Inovio Presentation
Thursday, September 12, 2013
10:55 AM ET

A live and archived webcast of the presentation will be accessible on the homepage of Inovio’s website under the webcast tab at www.inovio.com.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today’s cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio’s lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis C virus. Partners and collaborators include the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended June 30, 2013, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com

(CSUN) High-Efficient Mono Cells Certified Conversion Efficiency Record of 20.26%

NANJING, China, Sept. 3, 2013 — China Sunergy Co., Ltd. (NASDAQ: CSUN) (“China Sunergy” or “the Company”), a specialized solar cell and module manufacturer, today announced that its new generation of high-efficient mono-crystalline solar cells have reached 20.26% conversion efficiency in the pilot research and development (“R&D”) line, and have received certification recently from the Fraunhofer Institute for Solar Energy Systems ISE (“Fraunhofer ISE”), the largest solar energy research institute in Europe.

The new generation of high-efficient mono-crystalline solar cells combines the Company’s Waratah and QSAR cell technology in a new design structure that enables it to achieve high conversion efficiency using normal wafers. The new conversion efficiency record of 20.26% was confirmed by Fraunhofer ISE as the leading level among all photovoltaic enterprises in China and has surpassed the benchmark of 20% mono-crystalline cells conversion efficiency set by the eight development guidelines issued by the State Council for China’s photovoltaic industry in July 2013.

The high-efficient mono-crystalline solar cells offer outstanding cost advantage and space reduction, making them ideal for rooftop applications. China Sunergy has installed high-efficient mono-crystalline solar cell production lines with the capacity of 70MW, and a corresponding module production line with the capacity of 15MW in its newly completed R&D center. The company plans to start commercial mass production by the end of this year.

Dr. Jianhua Zhao, Chief Technology Officer of China Sunergy, said, “As one of the key members for China’s 863 program in developing and commercializing high-efficient and low-cost crystalline silicon solar cells, we are committed to developing cutting-edge and strategic solar technologies. We are proud of our record achievement, and aim to promptly deploy this new breakthrough for large-scale commercial application. Our success validates the hard work and diligence of our dedicated R&D team, and we remain determined to further advance the state of the art and to foster healthy and sustainable development for solar energy.”

About China Sunergy Co., Ltd.

China Sunergy Co., Ltd. (NASDAQ:CSUN) designs, manufactures and delivers high efficiency solar cells and modules to the world from its production centers based in China and Turkey. China Sunergy also invests in high potential solar projects. Founded in 2004, China Sunergy is well known for its advanced solar cell technology, reliable product quality, and excellent customer service.

For more information, please visit http://www.csun-solar.com.

Investor and Media Contacts:

China Sunergy Co., Ltd.

Elaine Li
Phone: + 86 25 5276 6696
Email: Elaine.li@chinasunergy.com

Asia Bridge Group Limited

Wendy Sun
Phone: + 86 10 8556 9033
Email: wendy.sun@asiabridgegroup.com

Safe Harbor Statement

This announcement may contain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts in this announcement are forward-looking statements. These forward-looking statements are based on current expectations, assumptions, estimates and projections about the Company and the industry, and involve known and unknown risks and uncertainties, including but not limited to, the Company’s failure to maintain its listing qualification due to, among other things, volatility in the Company’s ADS price; the Company’s ability to raise additional capital or renew existing bank borrowings as they become due to finance the Company’s activities; the Company’s customers’ financial condition and creditworthiness, and their ability to settle accounts receivables; the effectiveness, profitability, and the marketability of its products; litigations and other legal proceedings, including any decisions by the US International Trade Committee and Department of Commerce on the petitions filed; the economic slowdown in China and elsewhere and its impact on the Company’s operations; demand for and selling prices of the Company’s products, execution of our strategy to expand into downstream solar power businesses, the future trading of the common stock of the Company; the ability of the Company to operate as a public company; the period of time for which its current liquidity will enable the Company to fund its operations; the Company’s ability to protect its proprietary information; general economic and business conditions; the volatility of the Company’s operating results and financial condition; the Company’s ability to attract or retain qualified senior management personnel and research and development staff; future shortage or availability of the supply of raw materials; impact on cost-competitiveness as a result of entering into long-term arrangements with raw material suppliers and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.

(HSOL) to Announce Q2 2013 Financial Results on September 9, 2013

SHANGHAI, Sept. 3, 2013 — Hanwha SolarOne Co., Ltd. (“Hanwha SolarOne” or the “Company”) (NASDAQ: HSOL), a vertically integrated manufacturer of silicon ingots, wafers and photovoltaic (“PV”) cells and modules in China, today announced that it will release its unaudited financial results for the second quarter of 2013 before the market opens on Monday, September 9, 2013.  On the same day, management will host a conference call to discuss the results at 9:00 AM Eastern Time (9:00 PM Shanghai time).

Conference Call

Mr. Ki-Joon HONG, Chairman and CEO; Mr. Min-Su KIM, President; Mr. Jay SEO, Chief Financial Officer; and Mr. Paul Combs, Vice President of Investor Relations, will discuss the results and take questions following the prepared remarks.

The dial-in details for the live conference call are as follows:

Passcode: HSOL

A live webcast of the conference call will be available on the investor relations section of the Company’s website at: www.hanwha-solarone.com.  A replay of the webcast will be available for one month.

A telephone replay of the call will be available for seven days after the conclusion of the conference call.  The dial-in details for the replay are as follows:

Conference ID 40762003

Replay time period: 10/09/2013 12:00 ET – 17/09/2013 9:59 ET

About Hanwha SolarOne

Hanwha SolarOne Co., Ltd. (NASDAQ: HSOL) is a vertically integrated manufacturer of silicon ingots, wafers, PV cells and modules.  Hanwha SolarOne offers high-quality, reliable products and services at competitive prices.  Partnering with third party distributors, OEM manufacturers, and system integrators, Hanwha SolarOne serves the utility, commercial/government, and residential markets.  The company maintains a strong worldwide presence with employees located throughout Europe, North America, and Asia and embraces environmental responsibility and sustainability with an active role in the voluntary photovoltaic recycling program.  The Company benefits from its strategic partnership with its largest shareholder Hanwha Group who is active in solar project development and financing and plans to produce polysilicon in the future.  For more information visit: www.hanwha-solarone.com.

For further information, please contact:

Investor Contact:
Paul Combs
V.P. of Investor Relations
6^th Floor, Yongda International Tower
2277 Longyang Road, Shanghai, PRC 201204
Tel:  86-21-3852 1533 / Mobile:  86 138 1612 2768
E-mail: paul.combs@hanwha-solarone.com

(ADXS) Announces Three Abstracts Accepted by Society for Immunotherapy of Cancer Meeting

Advaxis, Inc. (OTCQB:ADXS) (“Advaxis” or the “Company”), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that three abstracts describing research with Advaxis Lm-LLO immunotherapies have been selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 28^th Annual Meeting, November 8-10, 2013 at the Gaylord National Hotel & Convention Center in National Harbor, MD.

The abstract titled “Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment” has been selected for oral presentation during the session, “Tumor Microenvironment and Innate Cells Recognition” on November 8, 2013 from 9:40 AM to 12:00 PM. Anu Wallecha, Ph.D., Director of Research and Development at Advaxis, will report on the localized effects of Lm-LLO immunotherapies on the tumor microenvironment in preclinical studies using transplantable mouse models.

The abstract titled “ADXS11-001 immunotherapy targeting HPV-E7: Updated survival and safety data from a Phase 2 study in Indian women with recurrent/refractory cervical cancer” has been selected for poster presentation during the Vaccine session. Robert Petit, Ph.D., Chief Scientific Officer of Advaxis, will present final 18-month survival and updated safety data from the ongoing trial.

The abstract titled “Biomarker identification in serum samples from patients with recurrent cervical cancer treated with ADXS11-001 immunotherapy” has been selected for poster presentation during the session “Biomarkers and Immunoscoring”. Poonam Molli, Ph.D., Senior Scientist at Advaxis, will report on the correlation of changes in cytokine and chemokine levels pre- and post-dosing with ADXS11-001 from the Phase 2 study in Indian women with recurrent/refractory cervical cancer.

“The three presentations of Advaxis data at SITC reflect our growing understanding of the unique attributes of the Advaxis platform technology for immunotherapies. Dr. Wallecha’s presentation will highlight the ability of Lm-LLO immunotherapy to counteract immune suppressor cells that enable persistence of the tumor. We will report final 18-month survival and final tumor response data from our 110 patient Phase 2 study in India in women with recurrent cervical cancer. Dr. Molli’s presentation will illustrate the remarkable immune stimulation that occurs in patients after treatment with ADXS11-001. Together, these data paint a picture of an immunotherapy that has a strong positive impact on the immune system while at the same time counteracting immune suppression in the tumor microenvironment that can lead to apparent prolonged survival and objective tumor responses from a single immunotherapeutic agent,” commented Dr. Petit.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein(s) that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.

ADXS-HPV is currently being evaluated in four clinical trials for human papillomavirus (HPV)-associated cancers: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI U.S. study, Clinical Trials.gov Identifier NCT01266460), head & neck cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study, Clinical Trials.gov Identifier NCT01671488). Advaxis has over 15 distinct immunotherapies in various stages of development, developed directly by Advaxis and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the University of Pennsylvania, the Georgia Regent University Cancer Center, the Karolinska Institutet, and others.

For more information please visit: http://www.advaxis.com

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding the ability of ADXS-HPV to lead to apparent prolonged survival and objective tumor responses from a single immunotherapeutic agent. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2012, which is available at http://www.sec.gov. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

(HOTR) Signs Lease for New Hooters Restaurant in Pretoria, South Africa

(GALE) Initiates RELIEF Patient Registry for Abstral Sublingual Tablets

• RELIEF: Rapid Evaluation of Lifestyle, Independence, and Elimination of breakthrough cancer pain with Freedom from oral discomfort through the use of Abstral® (fentanyl) Sublingual Tablets
• Galena debuts Abstral campaign at PAINWeek September 4-7, 2013 in Las Vegas
• Galena to generate sales revenue in 2013 with significant progress towards Abstral® commercial launch in the fourth quarter.

PORTLAND, Ore., Sept. 3, 2013 — Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company commercializing and developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the initiation of the Company’s Institutional Review Board (IRB)-approved cancer patient registry study entitled RELIEF: Rapid Evaluation of Lifestyle, Independence, and Elimination of breakthrough cancer pain with Freedom from oral discomfort through the use of Abstral® (fentanyl) Sublingual Tablets. RELIEF is a post-marketing multicenter trial to assess Abstral for breakthrough cancer pain (BTcP) in opioid-tolerant cancer patients. Abstral is available to patients and health care professionals at pharmacies nationwide, and recruitment and enrollment for the registry trial is underway.

RELIEF is a registry study to be completed by enrolled patients over a thirty day period while using Abstral for treatment of their breakthrough cancer pain. Approximately 2,500 patients are expected to enroll in the program.

Galena also announced the debut of Abstral’s sales and marketing campaign at the PAINWeek conference taking place September 4-7, 2013 in Las Vegas, NV. With over 1,800 attendees, PAINWeek is one of the nation’s largest pain conferences for healthcare professionals with an interest in pain management. Galena’s commercial team is now fully staffed and on schedule for a fourth quarter launch with senior level executives and a highly experienced sales force. The Company’s patient assistance and reimbursement program has been implemented and is being accessed by patients across the country.

“With collaboration and support from the physician community, we are excited to initiate our RELIEF trial and debut Abstral this week, which we believe is the the best product in this class of drugs for patients suffering from breakthrough cancer pain,” said Mark J. Ahn, President and CEO. “Abstral’s product features, including its ease of use, and lack of product disposal issues, make it an important treatment option for these patients. The RELIEF registry is a critical initiative that will help assess the attributes of the drug and provide a sizeable data set to support physicians who prescribe Abstral. The initiation of our registry program ahead of our official launch is an important first step in our overall commercial plan as the second half of the year will be transformational for Galena, as we generate sales and become a revenue producing organization.”

RELIEF was developed with input from leading pain treatment specialists and is intended to provide Galena with valuable insight from patients taking Abstral by assessing a variety of characteristics including pain severity, ease of use, patient satisfaction, and overall quality of life. Galena expects to share the RELIEF results with physicians to provide relevant feedback as they address the challenges in treating patients suffering from BTcP.

About Abstral® (fentanyl) Sublingual Tablets

Abstral® (fentanyl) Sublingual Tablets are an important treatment option for inadequately controlled breakthrough cancer pain (BTcP) which impact 40%-80% of cancer patients. Abstral is approved by the FDA, and is a sublingual (under the tongue) fentanyl tablet indicated for the management of breakthrough pain in patients with cancer, 18 years of age and older, who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain. The innovative Abstral formulation delivers the analgesic power and increased bioavailability of micronized fentanyl in a more convenient sublingual tablet which rapidly dissolves under the tongue in seconds, provides rapid relief of breakthrough pain in minutes, and matches the duration of the entire pain episode. Abstral is available through the transmucosal immediate-release fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) program. For additional important safety information, see the full Prescribing Information for Abstral available at www.abstral.com.

About Breakthrough Cancer Pain

Breakthrough cancer pain is defined as a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain. Breakthrough cancer pain occurs in 40-80 percent of patients who are already receiving chronic, long-acting opioid pain management and yet have episodes of severe tumor- and treatment-related cancer pain. Breakthrough pain occurs frequently in these patients, particularly as they try to conduct normal daily activities, with a mean number of episodes of 4 per day (average range 1-14 per day) and a median duration of 30 minutes (range 1-240 minutes). The wide range of time to relief of these severe pain episodes leads to high levels of distress and impaired quality of life experienced by patients.

About Galena Biopharma

Galena Biopharma, Inc. (Nasdaq:GALE) is a Portland, Oregon-based biopharmaceutical company commercializing and developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. For more information visit www.galenabiopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to Galena’s expectations for commercialization of Abstral® and the development of Galena’s NeuVax™ product candidate. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the possibility that Galena’s commercialization of Abstral may be delayed or prove unsuccessful. Galena’s business and operations and the development of its product candidates also are subject to the risks and uncertainties identified under “Risk Factors” in Galena’s Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 filed with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Galena does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release.

CONTACT: Remy Bernarda
         Senior Director, Communications
         (503) 405-8258
         rbernarda@galenabiopharma.com